Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(50%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_1
3
50%
Ph phase_3
1
17%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)

Detailed Status

Recruiting3
Not yet recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 31 (16.7%)
N/A2 (33.3%)

Trials by Status

not_yet_recruiting117%
completed117%
recruiting350%
terminated117%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
recruitingphase_3

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664
not_yet_recruitingnot_applicable

Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor

NCT07004387
recruitingphase_1

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

NCT05475210
terminatedphase_1

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

NCT02592707
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06441331Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Recruiting
NCT06878664Phase 3

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Recruiting
NCT07004387Not Applicable

Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor

Not Yet Recruiting
NCT05475210Phase 1

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Recruiting
NCT02592707Phase 1

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Terminated
NCT02575170Not Applicable

Amino Acid Infusion in Mothers Before and During Cesarean Delivery

Completed

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6